Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations

Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of various human cancers. We examined the therapeutic pote...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Haematologica
Main Authors: Lim, Su Lin, Damnernsawad, Alisa, Shyamsunder, Pavithra, Chng, Wee Joo, Han, Bing Chen, Xu, Liang, Pan, Jian, Pravin, Dakle Pushkar, Alkan, Serhan, Tyner, Jeffrey W., Koeffler, H. Phillip
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545861/
https://ncbi.nlm.nih.gov/pubmed/30606790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.201483
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki